|
Treatment-related adverse events
|
n (%)
|
|---|
|
Any grade
|
≥grade 2
|
|---|
|
All TRAEs
|
31 (53%)
|
18 (31%)
|
|
Common TRAEs
|
25 (43%)
|
10 (17%)
|
|
Anorexia
|
9 (16%)
|
3 (5%)
|
|
Malaise
|
6 (10%)
|
0
|
|
Nausea
|
3 (5%)
|
0
|
|
Upper gastrointestinal hemorrhage
|
2 (3%)
|
2 (3%)
|
|
Fever
|
2 (3%)
|
0
|
|
Localized edema
|
2 (3%)
|
0
|
|
Creatinine increased
|
2 (3%)
|
0
|
|
Dysgeusia
|
2 (3%)
|
0
|
|
Pruritus
|
2 (3%)
|
0
|
|
Nail change
|
2 (3%)
|
0
|
|
Anemia
|
1 (2%)
|
1 (2%)
|
|
Palpitations
|
1 (2%)
|
1 (2%)
|
|
Colonic perforation
|
1 (2%)
|
1 (2%)
|
|
Neutrophil count decreased
|
1 (2%)
|
1 (2%)
|
|
Dyspnea
|
1 (2%)
|
1 (2%)
|
|
Pleural effusion
|
1 (2%)
|
1 (2%)
|
|
Eosinophilia
|
1 (2%)
|
0
|
|
Constipation
|
1 (2%)
|
0
|
|
Platelet count decreased
|
1 (2%)
|
0
|
|
Proteinuria
|
1 (2%)
|
0
|
|
Cough
|
1 (2%)
|
0
|
|
Immune-related adverse events (irAEs)
|
20 (35%)
|
10 (17%)
|
|
Liver enzyme elevation
|
7 (12%)
|
3 (5%)
|
|
Peripheral sensory neuropathy
|
4 (7%)
|
2 (3%)
|
|
Rash maculopapular
|
4 (7%)
|
1 (2%)
|
|
Colitis
|
4 (7%)
|
0
|
|
Hypothyroidism
|
2 (3%)
|
2 (3%)
|
|
Hyperglycemia
|
1 (2%)
|
1 (2%)
|
|
Esophagitis
|
1 (2%)
|
1 (2%)
|
|
Hypopituitarism
|
1 (2%)
|
1 (2%)
|
